Chemistry:AKO-001

From HandWiki

AKO-001, or AKO001, is a combination of the non-selective serotonin receptor agonist and serotonergic psychedelic dimethyltryptamine (DMT) and an undisclosed "specific plant bioactive" which is under development for the treatment of stroke.[1][2][3] While the "specific plant bioactive" in the combination and the action of this compound have not been disclosed, certain plant compounds, such as the β-carboline harmine in Banisteriopsis caapi, are reversible monoamine oxidase A (MAO-A) inhibitors and inhibit the metabolism of DMT, in turn greatly potentiating DMT and allowing it to become orally active.[4][5][6] AKO-001 is being developed by Akome Biotech.[1][2][3] As of March 2022, the drug is in the preclinical research stage of development.[1][2][3]

See also

References

  1. ↑ 1.0 1.1 1.2 "AKO 001". 8 March 2022. https://adisinsight.springer.com/drugs/800064283. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on AKO-001 with Synapse". 23 January 2025. https://synapse.patsnap.com/drug/171edb8562a5424a87c696cb1058c172. 
  3. ↑ 3.0 3.1 3.2 "AKO-001 Drug Profile". 2 September 2022. https://pryzm.ozmosi.com/product/25805. 
  4. ↑ "Ayahuasca: pharmacology, safety, and therapeutic effects". CNS Spectrums: 1–9. November 2024. doi:10.1017/S109285292400213X. PMID 39564645. 
  5. ↑ "Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors". Cellular and Molecular Life Sciences 81 (1): 395. September 2024. doi:10.1007/s00018-024-05353-6. PMID 39254764. 
  6. ↑ "Monoamine Oxidase Inhibition by Plant-Derived β-Carbolines; Implications for the Psychopharmacology of Tobacco and Ayahuasca". Frontiers in Pharmacology 13. 2022. doi:10.3389/fphar.2022.886408. PMID 35600851. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:AKO-001&oldid=4036499"